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Abstract. The responsiveness of neoadjuvant chemotherapy in Triple Negative Breast 
Cancer (TNBC) needs determination to prevent overtreatment with chemoresistance 
regimen. A total of 60 consented patients from Haji Adam Malik and Bunda Thamrin 
Hospital were included in this cohort prospectie study. Patients with heart, kidney, liver 
disease, history of surgery, chemotherapy, or hormonal therapy were excluded. Apoptotic 
indexes were taken from all subjects before and after neoadjuvant chemotherapy. After 3 
cycles of neoadjuvant chemotherapy, 31 subjects (51.7%) did not show clinical response 
while 29 subjects (48.3%) had clinical response. There was no significant difference of 
apoptotic index before and after neoadjuvant chemotherapy (5.47+1.38 vs 5.52+1.08 pg/mL). 
There was also no significant relationship between apoptosis index and clinical response 
(p=0.993). This study showed that apoptotic index fails to be neoadjuvant chemotherapy 
response predictor in triple negative breast cancer. Further research with larger samples is 
needed to confirm this result. 
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1. Introduction 
Triple Negative Breast Cancer (TNBC) accounts for 17-21% of breast cancer case [1]. but 
accounts for the worst prognosis of all breast cancers [2]. The absence of hormonal receptors 
makes chemotherapy an important role in the treatment of TNBC [3]. Multicentre studies showed 
that 36% of TNBC patients receiving neoadjuvant chemotherapy showed complete clinical 
response and a significant good prognosis for disease free survival (p=0.001) [4]. In the EORTC 
study, it was reported that almost 23% of patients being enabled for breast conserving surgery 
after neoadjuvant chemotherapy. However, there were also many chemoresistance cases making 
the neoadjuvant chemotherapy almost had no benefit but only yielded harmful side effects [5]. 
Biomarker for that can accurately identify a patient with sensitivity for chemotherapy is needed 
[6]. This study will examine the expression of apoptotic index (AI), which is commonly used as 
a measure of apoptotic or apoptotic cell count per 1000 tumor cells. 
2. Methodology 
This prospective cohort was conducted from June 2015 to February 2017. As many as 60 TNBC 
subjects undergoing surgery in Haji Adam Malik General Hospital and Bunda Thamrin Hospital 
were included in this study. They must approve the informed consent and had a Karnofsky 
scale >70. Exclusion criteria when there is morbidity of heart disease, kidney, liver, history of 
surgery, hormonal therapy, or previous chemotherapy. The parameters of this study were 
apoptotic index pre-chemotherapy and post- neoadjuvant chemotherapy. The TUNEL assayed-
apoptotic index were done to all subjects before and after neoadjuvant chemotherapy admin-
istration. The chemotherapy regimen were given based on the hospitals protocol in Medan, 
Indonesia. Data were then collected and analyzed by SPSS 17.0. 
3. Results 
A total of 60 TNBC patients followed the study until completion. Subjects ranged from 30 to 73 
years old with the majority of premenopausal subjects (56.7%). As many as 75% of patients 
diagnosed in stage IIIB and 43.3% had T3 tumor size, 80% IDC histology type, and 41.7% were 
in grade II. After 3 cycles of neoadjuvant chemotherapy, 31 subjects (51.7%) did not show clinical 
response while 29 subjects (48.3%) had clinical response (Table 1). 
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Table 1 Demographics Data of Subjects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this study, the mean apoptotic index before neoadjuvant chemotherapy was 5.47 + 1.38 pg/mL 
and after neoadjuvant chemotherapy was 5.52 + 1.08 pg/mL. The result of t-paired test showed 
that there was no significant difference between mean of AI postchemotherapy and 
preechemotherapy (p=0.819) with only increase of 0.05 + 1.68 pg/mL (Table 2). Most of the 
subjects in the group that responded nor responded clinically to chemotherapy showed an 
increased apoptotic index (51.7%). However, Phi and Cramer's V correlation analysis showed no 
significant relationship between apoptosis index (p = 0.993) and clinical response (Table 3). 
Table 2 Mean Difference of Apoptotic Index Postchemotherapy and Prechemotherapy 
Parameter Pre-chemotherapy 
(pg/mL) 
Post-chemotherapy 
(pg/mL) 
Difference p 
Apoptotic 
index 
5.47 + 1.38 5.52 + 1.08 0.05 + 1.68 0.819 
 
 
 
 
 
 
 
Characteristics Percentage 
Age (years old)   
< 35 8 (13.3%) 
35 – 40 11 (18.3%) 
41 – 50 16 (26.7%) 
51 – 60 19 (31.7%) 
>60 6 (10.0 %) 
Menopausal status   
Premenopause 34 (56.7%) 
Postmenopause 26 (43.3%) 
Stage  
IIIA 15 (25.0%) 
IIIB 45 (75.0%) 
Tumor size    
Tx  3 (5.0%) 
T1 1 (1.7%) 
T3 26 (43.3%) 
T4 30 (5.0%) 
Histological type   
IDC  48 (80.0%) 
ILC 12 (20.0%) 
Grade  
I 9 (15%) 
II 26 (43,33%) 
III 25 (41,66%) 
Chemotherapy 
response 
 
Response 29 (48.3%) 
No response 31 (58.7%) 
Sumatera Medical Journal (SUMEJ) Vol. 02, No. 02, 2019                                                            4 
Table 3 The Relationship Between Apoptotic Index and Neoadjuvant 
 Chemotherapy Response 
Apoptotic 
index 
Clinical Response of Neoadjuvant 
Chemotherapy 
Total p 
No Response Good Response 
Unchange 4 (12.9%) 4 (6,7%) 8 (13.3%)  
Decrease 11 (18.3%) 10 (16,7%) 21 
(35.0%) 
0.993 
Increase 16 (26.7%) 15 (25,0%) 31 
(51.7%) 
 
Total 31 (51.7%) 29 (48,3%) 60 
(100%) 
 
 
4. Discussion 
The age-specific prevalence pattern for TNBC was not fully understood until SEER collected data 
from 1997-2002 [7]. In this study, subjects aged 27 to 73 years old that mostly aged between 51 
and 60 years (31.7%). Prevalence of subjects aged 35 to 50 years old was 76.7%. This result was 
in accordance with SEER survey that found peak incidence cases of TNBC from 35-60 years, and 
afterwards not much different. The population based study by Ambrosone showed that 2.9 times 
the increased risk of TNBC in women at this age was due to unknown increase in the use of oral 
contraceptives [8]. However, there is a research controversy by Stark, who observed increased 
1.9 times risk of TNBC occurred at younger ages. But, this can be due to the researchers 
comparing it with luminal breast cancer A [9]. Phipps in Americans showing that menopausal age 
was not associated with an increased risk of TNBC [10], as did other studies by Xing in China 
[11] and Yang in Poland [12] but increased the risk of luminal breast cancer A. Phipps even tried 
hormonal therapy on TNBC patients and found no improvement. The study also showed a nearly 
equal proportion between premenopausal and postmenopausal patients, 56.66% and 43.33%, 
respectively [10]. 
Based on table 1, there were 31 samples (51.7%) that did not respond to neoadjuvant 
chemotherapy and 29 samples (48.3%) that response to neoadjuvant chemotherapy. This 
proportion was higher than that of Yarso (2012), which showed only 15% of clinical responses 
[13]. Although Torrisi (2010) reported 77.5% [14]. Von Minckwitz (2014) found that the addition 
of neoadjuvant chemo-therapy carboplatin to the regimen taxan, anthracyclin, and targeted 
therapies significantly increase the propor-tion of patients achieving a complete response. This 
suggested that neoadjuvant chemotherapy could reduce the size of the tumor and eradicated 
almost half the TNBC cases [15]. Otherwise, some unresponse patients to be overtreated because 
of the unpredictability of TNBC. This condition should be prevented by the discovery of 
prognostic factor that can predict neoadjuvant chemotherapy response earlier. 
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Reviewing the apoptotic index, there was no significant mean difference between postoperative 
and postte-motherapy (p = 0.819) and no significant differences were found between apoptotic 
index and TNBC chemo-therapy response (p=0.993). The proportion of the increase or decrease 
in the apoptotic index was almost com-parable between those who responded and unrespond to 
neuroadjuvant TNBC. This result was similar to Yang (2001) which showed that maybe the 
apoptotic index low due to low concentration of doxorubicin given. In MCF-7 cells, 18-hour 
doxorubicin were exposed that resulted in caspase activation and other apoptotic sub-strates in 
line with the addition of 2-10 microM [16]. Unlike ODonovan (2003) study in 103 breast tissue 
samples, they showed that Caspase-3 precursor and active form were higher in breast cancer than 
normal tissue (p=0.0188; p=0.0002) [17]. Similarly, Sharma (2009) showed that tumor biology 
markers (Bcl-2, Apoptotic Index and Caspase-3) changes occurred 24-48 hours after first neoad-
juvant chemotherapy cycles. These markers cpuld be as a factors to predict the response of 
chemotherapy, but to prove them statistically, need research with a larger sample size [18]. 
It has been shown in the previous data that there was no significant increase in apoptosis index 
after neoadju-vant chemotherapy. The author concluded that apoptotic index was not able to be a 
response predictor of chemo-therapy in TNBC. However, further research was suggested to 
investigate this issue using larger samples. 
5. Conclusion 
There was no significant difference between apoptotic index and clinical chemotherapy response 
to neoadjuvant chemotherapy on triple negative breast cancer. Further research with larger 
samples is needed to determine the role and pathway of chemotherapy induced caspase 3 rise. 
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